Abbott Laboratories reported second-quarter 2026 adjusted earnings of $1.31 per share, beating the Zacks Consensus Estimate by 2.34%, while sales rose 13% to $12.59 billion and topped estimates by 0.91%. Medical Devices sales grew 9% to $5.85 billion, led by electrophysiology and diabetes care, and Diagnostics surged 42.3% to $3.09 billion following the Exact Sciences acquisition, with Cancer Diagnostics delivering double-digit comparable growth. Nutrition sales declined 3.1% to $2.14 billion due to lower volumes and strategic pricing actions, while Established Pharmaceuticals rose 8.4% to $1.50 billion. Abbott raised its full-year 2026 adjusted earnings guidance to a range of $5.45 to $5.60 per share and reaffirmed its comparable sales growth forecast of 6.5% to 7.5%. The stock rose 3.2% in pre-market trading following the announcement.
Abbott LaboratoriesAbbott beat Q2 earnings and revenue estimates and raised full-year guidance.
Charles River Laboratories
CVS Health Corp
Phibro Animal Health Corporation